REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a ...
Salt Lake City-based Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has secured an irrevocable commitment from Evotec SE, a significant shareholder of Exscientia plc, to support Recursion's proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback